Leading Ohio Critical Access Hospital Adopts Masimo Root® with Radius-7®, Radical-7®, and Patient SafetyNet™ to Create Hospital-Wide Wireless Monitoring and Clinician Notification System
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160728005606/en/
Masimo Patient SafetyNet is a supplemental system that enables
information from bedside and tetherless wearable monitors to be
accessible from remote locations and relays alarm notifications to
clinicians. Used with Root, Patient SafetyNet allows hospitals to
automate the transfer of patient vital signs, including temperature and
blood pressure, to patients’ medical records, which may help improve
nursing workflows. Root, available with Radical-7 or Radius-7, provides
monitoring of Masimo rainbow SET™ parameters such as oxygen saturation
(SpO2) and total hemoglobin (SpHb), and is expandable to
monitor additional parameters, such as respiration rate from RAM™
(rainbow® acoustic monitoring). Radius-7 provides continuous
tetherless wearable monitoring of
UH Geneva is part of the University Hospitals system, which employs over
26,000 physicians and employees in
“Patient safety is extremely important to us,” said Dr.
“UH Geneva provides a compelling example of the standard of care that
more and more community hospitals are adopting,” said
@MasimoInnovates | #Masimo
Needham D, Korupolu R, Zanni J, Pradhan P, Colantuoni E, Palmer J,
Brower R, Fan E. "Early Physical Medicine and Rehabilitation for
Patients With Acute Respiratory Failure: A Quality Improvement
Project." Archives of Physical Medicine and Rehabilitation.
Vol 91, Issue 4, PP 536–542,
- Ronnenbaum J, Weir J, Hilsabeck T. Earlier mobilization decreases length of stay in the intensive care unit. J Acute Care Phys Ther. 2012;3(2):204-210.
*The use of the trademark SafetyNet is under license from
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
About University Hospitals
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Radical-7®, Root® with Radius-7®, and Patient SafetyNet™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo Radical-7, Root with Radius-7, and Patient SafetyNet, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the